XTL Biopharmaceuticals
XTLB
4 hedge funds and large institutions have $76K invested in XTL Biopharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 0 closing their positions.
33% more funds holding
Funds holding: 3 → 4 (+1)
0.12% more ownership
Funds ownership: 0.69% → 0.81% (+0.12%)
12% less capital invested
Capital invested by funds: $86K → $76K (-$10K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$10.4K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$2.05K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$867 |
Top Sellers
XTLB Hedge Fund Activity: Q1 2018 in Review
4 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q1 2018, worth a combined $76K — down 12% from $86K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new XTLB positions and 0 closed out — a net gain of 1 holder — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $10.4K.
- 4 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q1 2018, up from 3 in Q4 2017.
- Funds reported $76K of XTL Biopharmaceuticals stock for Q1 2018, down 12% quarter-over-quarter.
- 1 fund opened new XTL Biopharmaceuticals positions in Q1 2018 and 0 closed out, a net change of +1 holder.
- The largest XTL Biopharmaceuticals buyer in Q1 2018 was Morgan Stanley, an estimated $10.4K added.
Based on aggregated 13F filings for Q1 2018.